Login
$TNGX
$24.22 +$0.05 (0.21%) After hours

$TNGX 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free survival (PFS) rate in patients with 2L/3L ...

23 Oct 2026 8-K: Regulation FD Disclosure; Other Events

Disclaimer and safe harbor statement Certain statements in this presentation may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statem...

11 Aug 2026 8-K: Other Events

Securities Registered under Registration Statement on Form S-3ASR

11 Aug 2026 8-K: Results of Operations and Financial Condition

Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data

06 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

23 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appoi...

10 Jun 2026 8-K: Entry into a Material Definitive Agreement

Tango Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with J.P. Morgan Securities LLC (“J.P. Morgan”), Leerink Partners LLC (“Leerink Partners”) and each of the other Underwriters named in Schedule A he...

08 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.2 Vopimetostat and RAS(ON) combination data June 8, 2026

04 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

The 2026 annual meeting of stockholders (the “Annual Meeting”) of Tango Therapeutics, Inc. (the “Company”) was held in a virtual-only format on June 4, 2026 at 9:00 a.m., Eastern Time via live webcast. Proxies were solicited pursuant to ...

13 May 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026

08 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

This confirms our discussions relating to the end of your at-will employment with Tango Therapeutics, Inc. (“Tango” or the “Company”), which is a termination by the Company without Cause for purposes of the Employment Agreement between y...

15 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

This Employment Agreement (“Agreement”) is made between Tango Therapeutics, Inc., a Delaware corporation (the “Company”), and Matthew Gall (the “Executive”), and is effective as of April 15, 2026 (the “Effective Date”).

05 Mar 2026 8-K: Results of Operations and Financial Condition

Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment

08 Jan 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

This Employment Agreement (“Agreement”) is made between Tango Therapeutics, Inc., a Delaware corporation (the “Company”), and Malte Peters, M.D. (the “Executive”), and is effective as of the Effective Date, as defined in Section 23 herein.

05 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

BOSTON, January 5, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the app...

21 Nov 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

On November 21, 2025, Tango Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”), pursuant to which the Company may sell, from time to time, at its option, shar...

04 Nov 2025 8-K: Results of Operations and Financial Condition

– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months –

24 Oct 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

Tango Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with Leerink Partners LLC (“Leerink Partners”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” whic...

23 Oct 2025 8-K: Results of Operations and Financial Condition; Other Events

Disclaimer and safe harbor statement Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango’s future financial and operating performance, ...

25 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support